Donesumab, a monoclonal antibody against RANK ligand is used for the treatment of:
Correct Answer: Osteoporosis
Description: Ans. (B) Osteoporosis(Ref: Principles of pharmacolpg HL Sharma and KK Sharma 2007/641)Receptor for activated nuclear factor kB (RANK) is present on osteoclast progenitors. Binding of RANK-ligand to these receptors causes differentiation and activation of osteoclast progenitors to mature osteoclasts. Donesumab is a monoclonal antibody that prevents the binding of RANK-ligand with RANK. This prevents activation of osteoclasts and it can therefore, be used in osteoporosis.Osteoblasts synthesize and release osteoprotegerin (OPG), identical with RANK, which functions as a 'decoy receptor'. OPG, thus inhibits the binding to RANK-L to RANK. Hence OPG analogs can be the potential therapeutic agents of osteoporosis.
Category:
Pharmacology
Get More
Subject Mock Tests
Practice with over 200,000 questions from various medical subjects and improve your knowledge.
Attempt a mock test nowMock Exam
Take an exam with 100 random questions selected from all subjects to test your knowledge.
Coming SoonGet More
Subject Mock Tests
Try practicing mock tests with over 200,000 questions from various medical subjects.
Attempt a mock test now